+

US20020034546A1 - Pharmaceutical composition containing a combination of a statin and aspirin and method - Google Patents

Pharmaceutical composition containing a combination of a statin and aspirin and method Download PDF

Info

Publication number
US20020034546A1
US20020034546A1 US09/824,364 US82436401A US2002034546A1 US 20020034546 A1 US20020034546 A1 US 20020034546A1 US 82436401 A US82436401 A US 82436401A US 2002034546 A1 US2002034546 A1 US 2002034546A1
Authority
US
United States
Prior art keywords
aspirin
statin
pharmaceutical composition
granules
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/824,364
Inventor
Ismat Ullah
Nemichand Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020034546(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US09/824,364 priority Critical patent/US20020034546A1/en
Publication of US20020034546A1 publication Critical patent/US20020034546A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a pharmaceutical composition which includes a statin cholesterol lowering agent and aspirin in a manner to minimize interaction of aspirin with the statin, for use in lowering cholesterol and reducing risk of a myocardial infarction, and to a method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition.
  • statins for lowering cholesterol and preventing or treating atherosclerosis and cardiovascular disease and cerebrovascular disease are well documented. In fact, it is not uncommon that patients having elevated cholesterol levels who are at high risk for a myocardial infarction take both a statin and aspirin. However, use of both a statin and aspirin may require special care to insure that drug interaction, including physical and chemical incompatibility, and side effects, are kept to a minimum while achieving maximum benefit from these drugs.
  • statins such as pravastatin, atorvastatin and cerivastatin
  • statins alkali salts
  • pravastatin is also a very acid labile compound.
  • pravastatin and aspirin are combined, the aspirin could cause pravastatin degradation which could result in lower bioavailability of pravastatin.
  • Aspirin is known for causing gastrointestinal bleeding when used for long-term therapy. It is therefore desirable in long-term aspirin therapy that the aspirin be provided in a form which minimizes side effects.
  • statin-aspirin formulation which provides for maximum cholesterol lowering and reduction of risk of a myocardial infarction without the undesirable side effects and drug interaction normally associated with use of such combination.
  • a pharmaceutical composition which includes a statin cholesterol lowering agent and aspirin, which provides for maximum patient benefits including maximum cholesterol lowering and reduced risk of a myocardial infarction with minimal physical and chemical incompatibility (including minimal statin:aspirin interaction), and reduced side effects normally associated with use of such drugs.
  • a method for lowering serum cholesterol, preventing or inhibiting or treating atherosclerosis, and/or reducing risk of or treating a cardiovascular event or disease including coronary artery disease and cerebrovascular disease wherein a pharmaceutical composition containing a combination of a statin cholesterol lowering agent and aspirin in a single dosage form, in a manner so as to minimize interaction of the statin and aspirin, is administered to a patient in need of treatment.
  • a pharmaceutical composition wherein the statin (including any statin cholesterol lowering agent) and aspirin are formulated together in a single tablet.
  • the tablet of the invention is preferably in the form of a bilayered tablet which includes a first layer and a second layer.
  • Aspirin in the form of granules of preselected size will be present in the first layer together with optional excipients as described hereinafter, while the statin will be present in the second layer which optionally may include one or more buffering agents (as necessary to prevent undesirable statin/aspirin interaction) and optionally one or more excipients as described hereinafter.
  • the bilayered tablet of the invention may include an outer protective coating or finishing layer as described hereinafter.
  • Another embodiment of the present invention comprises a cored tablet which includes a core and a buffering layer or outer coat which can be compressed onto the core as a dry coat.
  • the core will preferably include compressed aspirin granules while the buffering layer or outer coat will include a statin (including any statin cholesterol lowering agent) together with one or more buffering agents and optional excipients.
  • the so-described cored tablet may also optionally include an outer protective coating or finishing layer as described hereinafter.
  • a pharmaceutical composition which is in the form of a tablet or capsule which includes a mixture of aspirin granules having an enteric coating and particles or granules of a statin.
  • a pharmaceutical composition is provided which is in the form of a tablet or capsule which includes a mixture of aspirin granules having an enteric coating and particles or granules of a statin.
  • the statin may include any statin cholesterol lowering agent, but preferably is simvastatin, lovastatin or cerivastatin.
  • enteric coated aspirin granules as described above may be further coated with a protective coating or finishing layer.
  • the double coated particles of aspirin can be mixed with any statins such as pravastatin, atorvastatin, simvastatin, lovastatin, and cerivastatin powders or granules, and the mixture can be encapsulated or tableted as described herein.
  • further coating of the enteric coated aspirin particles is desired to minimize interaction of alkaline pravastatin, atorvastatin or cerivastatin with enteric coated aspirin.
  • composition of the invention includes granules of enteric coated aspirin and enteric coated statin (including any statin cholesterol lowering agent), in the same dosage form such as compressed tablets or capsules.
  • the tablets containing the enteric coated granules of aspirin and statin may also include an outer protective coating or finishing layer.
  • the composition of the invention may comprise a mixture of aspirin granules and statin (including any statin cholesterol lowering agent, preferably, simvastatin, lovastatin or enteric coated particles of pravastatin or particles of pravastatin, atorvastatin and cerivastatin containing an outer protective coating or finishing layer); the above mixture may take the form of compressed tablets or capsules (where the mixture can be encapsulated separately in two shots in the same capsule shells).
  • statin including any statin cholesterol lowering agent, preferably, simvastatin, lovastatin or enteric coated particles of pravastatin or particles of pravastatin, atorvastatin and cerivastatin containing an outer protective coating or finishing layer
  • statin including any statin cholesterol lowering agent, preferably, simvastatin, lovastatin or enteric coated particles of pravastatin or particles of pravastatin, atorvastatin and cerivastatin containing an outer protective coating or finishing
  • the pharmaceutical composition of the invention which includes a combination of a statin and aspirin is effective in preventing, reducing and/or treating elevated cholesterol levels (such as in hypercholesterolemia), atherosclerosis, cardiovascular events and disease including coronary events and cerebrovascular events, and coronary artery disease and/or cerebrovascular disease.
  • elevated cholesterol levels such as in hypercholesterolemia
  • atherosclerosis such as in hypercholesterolemia
  • cardiovascular events and disease including coronary events and cerebrovascular events
  • coronary artery disease and/or cerebrovascular disease such as in hypercholesterolemia
  • cardiac event(s) and “cardiovascular disease” as employed herein refer to coronary and/or cerebrovascular event(s) and disease including primary myocardial infarction, secondary myocardial infarction, myocardial ischemia, angina pectoris (including unstable angina), congestive heart failure, sudden cardiac death, cerebral infarction, cerebral thrombosis, cerebral ischemia, transient ischemic attack and the like.
  • CAD coronary artery disease
  • Cerebrovascular disease refers to diseases including atherosclerosis of the intracranial and/or extracranial arteries, cerebral infarction, cerebral thrombosis, cerebral ischemia, stroke, and/or transient ischemic attacks.
  • Aspirin will preferably be employed in the form of salicylic acid acetate also referred to as acetylsalicylic acid.
  • composition of the invention in the form of a tablet or capsule will include aspirin in amounts from about 10 to about 800 mg, preferably 50 to about 650 mg.
  • the aspirin for use in forming the pharmaceutical composition of the invention will preferably be in the form of granules having an average particle size within the range from about 10 ⁇ m to about 2 mm, more preferably from about 0.25 mm to about 1.0 mm.
  • Statin cholesterol lowering agents suitable for use herein will include HMG CoA reductase inhibitors such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin and other statins such as fluindostatin and preferably pravastatin, simvastatin, atorvastatin or cerivastatin.
  • HMG CoA reductase inhibitors such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin and other statins such as fluindostatin and preferably pravastatin, simvastatin, atorvastatin or cerivastatin.
  • the pharmaceutical composition of the invention will contain a statin such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in an amount as normally employed for such statin as exemplified in the 52nd edition of the Physician's Desk Reference (PDR) (1998).
  • a statin such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin
  • a statin such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in an amount as normally employed for such statin as exemplified in the 52nd edition of the Physician's Desk Reference (PDR) (1998).
  • PDR Physician's Desk Reference
  • a daily dosage of 10 to 40 mg may be employed; for lovastatin, a daily dosage of 10 to 80 mg may be employed, for simvastatin a daily dosage of 5 to 40 mg may be employed; for atorvastatin, a daily dosage of 10 to 80 mg may be employed, for fluvastatin, a daily dosage of 20 to 80 mg may be employed; and for cerivastatin, a daily dosage of 0.2-0.3 mg may be employed.
  • the first layer containing aspirin will also preferably include bulking agents such as lactose, microcrystalline cellulose, wood cellulose, corn starch, modified corn starch, calcium phosphate, sugar, dextrose, mannitol or sorbitol.
  • the bulking agent will be present in an amount from about 1 to about 90%, preferably from about 5 to about 85% by weight of the first layer containing aspirin.
  • the first layer may also include a tabletting lubricant, such as zinc stearate, magnesium stearate, calcium stearate, talc, carnauba wax, stearic acid, palmitic acid or hydrogenated vegetable oils and fats, in an amount within the range from about 0.01 to about 4%, and preferably 0.02 to about 2% by weight of the first layer.
  • a tabletting lubricant such as zinc stearate, magnesium stearate, calcium stearate, talc, carnauba wax, stearic acid, palmitic acid or hydrogenated vegetable oils and fats
  • the second layer of the bilayered tablet containing statin cholesterol lowering agent will usually include a bulking agent such as lactose, microcrystalline cellulose, modified corn starch, calcium phosphate or other bulking agent as set out above for the first layer, in an amount within the range from about 1 to about 90%, preferably from about 5 to about 85% by weight of the second layer.
  • a bulking agent such as lactose, microcrystalline cellulose, modified corn starch, calcium phosphate or other bulking agent as set out above for the first layer, in an amount within the range from about 1 to about 90%, preferably from about 5 to about 85% by weight of the second layer.
  • the second layer may include a binder such as corn starch, pregelatinized starch, polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, cellulsoe acetate and the like, in an amount within the range from about 0.5 to about 20%, preferably from about 1 to about 10% by weight of the second layer, and a tabletting lubricant such as magnesium stearate, zinc stearate, or other lubricant as set out above with respect to the first layer in an amount from about 0.01 to about 4%, preferably from about 0.02 to about 2% by weight of the second layer.
  • a binder such as corn starch, pregelatinized starch, polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, cellulsoe acetate and the like, in an amount within the range from about 0.5 to about 20%, preferably from about 1 to about 10% by weight
  • the buffering agents present in the second layer may include conventional acid buffers such as calcium carbonate, magnesium oxide, magnesium carbonate, magnesium hydroxide, aluminum hydroxide, dihydroxyaluminum sodium carbonate, aluminum magnesium hydroxide sulfate or aluminum hydroxide magnesium carbonate co-dried gel, or mixtures of one or more thereof, in amounts as needed to insure that the aspirin will be sufficiently buffered to inhibit GI side effects.
  • amounts of buffering agent within the range from about 10 to about 1000 mg, preferably from about 50 to about 500 mg will be employed depending upon the amount of aspirin present in the first layer.
  • the first layer containing aspirin may be prepared by conventional wet granulation or dry granulation (compaction) techniques.
  • the second layer containing statin and buffers may be prepared by conventional wet granulation or dry granulation (compaction) techniques.
  • the first and second layers may then be compressed and combined to form a bilayered tablet employing conventional bilayer tabletting equipment.
  • compositions which may optionally be present in either of the two layers include preservatives, stabilizers, anti-adherents or silica flow conditioners or glidants, such as Syloid brand silicon dioxide as well as antioxidants such as Vitamin E, Vitamin C, and folic acid, Vitamin B 6 and Vitamin B 12 .
  • the bilayer tablet of the invention may also include an outer protective coating layer which may comprise from 0 to about 15% by weight of the bilayer tablet.
  • the outer protective coating layer which is applied over the bilayered tablet may comprise any conventional coating formulations and will include one or more film-formers or binders, such as a hydrophilic polymer like hydroxypropylmethyl cellulose (HPMC) and a hydrophobic polymer like ethyl cellulose, cellulose acetate, polyvinyl alcohol-maleic anhydride copolymers, acrylic copolymers, ⁇ -pinene polymers, glyceryl esters of wood resins and the like, and one or more plasticizers, such as polyethylene glycol, triethyl citrate, diethyl phthalate, propylene glycol, glycerin, butyl phthalate, castor oil and the like.
  • film-formers or binders such as a hydrophilic polymer like hydroxypropylmethyl cellulose (HPMC) and a hydropho
  • the film formers are applied from a solvent system containing one or more solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and 1,1,1-trichloroethane.
  • solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and 1,1,1-trichloroethane.
  • the pharmaceutical composition of the invention in the form of a cored tablet wherein the aspirin forms the core, and statin plus buffering agent are present in a surrounding coat layer may be prepared employing conventional cored tablet technology.
  • the aspirin containing core including excipients and other ingredients as described for the first layer in the bilayered tablet of the invention
  • the buffering layer containing statin as well as excipients and other ingredients may be compressed onto the core as a dry coat.
  • the so-formed cored tablet may be coated with an outer protective coating layer as described above for the bilayered tablet.
  • composition of the invention is formed of tablets or capsules containing a mixture of enteric coated aspirin granules, and a statin such as lovastatin, simvastatin or cerivastatin, which may be in the form of a tablet or capsule.
  • a statin such as lovastatin, simvastatin or cerivastatin
  • the aspirin granules can be coated with conventional enteric polymers coatings in aqueous or non-aqueous systems.
  • enteric polymers coatings for example, Eudragit L-30D-55 (acrylic acid copolymers-Rohm Pharma) (5 to 25% solids) containing 10 to 15% of diethylphthlate (w/w) as plasticizer can be used in an aqueous system.
  • enteric polymer coating systems may be employed such as Eudragit R and S series resins, (acrylic acid copolymers-Rohm Pharma), cellulose acetate phthalate, cellulose acetate maleate, cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethylcellulose acetate succinate, and the like, and a suitable plasticizer such as triethyl citrate, diethyl phthalate, tributyl citrate, triacetin, dibutyl phthalate dibutyl sebicate, Myvacet 940, and other commonly used plasticizers as may be suitable for particular enteric polymers can be used. It will be appreciated that any polymer with suitable plasticizer can be used in aqueous or non-aqueous system to form an enteric coating on the aspirin granule or particle.
  • suitable plasticizer such as triethyl citrate, diethyl phthalate, tributyl citrate, triacetin, dibutyl
  • the enteric coated aspirin granules described above may be further coated with an outer protective finishing coat or layer as described hereinbefore.
  • the double coated aspirin granules can be mixed with a statin such as pravastatin, atorvastatin, simvastatin, lovastatin, fluvastatin or cerivastatin powders or granules and the mixture can be encapsulated or tableted as described above.
  • a statin such as pravastatin, atorvastatin, simvastatin, lovastatin, fluvastatin or cerivastatin powders or granules and the mixture can be encapsulated or tableted as described above.
  • statin pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin and cerivastatin
  • statins can optionally be enteric coated.
  • the statins can be coated in the form of pure drugs or after spheronization or agglomeration. The particles for coating do not need to be perfectly spherical. These could be rods or irregular particles.
  • the enteric coated particles of the two drugs (aspirin and statin) can be tableted or encapsulated together.
  • excipients fillers, binders, disintegrants, and lubricant, etc.
  • This statin:aspirin combination will minimize side effects of aspirin, and eliminate chemical incompatibility.
  • aspirin granules can be mixed with simvastatin, lovastatin and fluvastatin powder or granules for tabletting or for encapsulating.
  • aspirin granules can be mixed with enteric coated particles of pravastatin, cerivastatin and atorvastatin and the mixture can be tableted or encapsulated or the two granules can be encapsulated in two shots in the same capsule shells.
  • the pharmaceutical composition of the invention containing the combination of the statin cholesterol lowering drug and aspirin may be administered to mammalian species, such as monkeys, dogs, cats, rats, humans, etc., and, as described hereinbefore, may be incorporated in a tablet or capsule.
  • mammalian species such as monkeys, dogs, cats, rats, humans, etc.
  • the above dosage forms will also include the necessary carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), antioxidants such as Vitamin C and Vitamin E, as well as Vitamin B 6 , Vitamin B 12 , folic acid, sodium bisulfite, and the like.
  • the dose administered must be adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.
  • compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination.
  • Tablets of various sizes can be prepared, e.g., of about 2 to 2000 mg in total weight, containing the active substances in the ranges described above, with the remainder being a physiologically acceptable carrier of other materials according to accepted pharmaceutical practice. These tablets can, of course, be scored to provide for fractional doses in some cases. Gelatin capsules can be similarly formulated.
  • Liquid formulations can also be prepared by dissolving or suspending one or the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsful.
  • Such dosage forms can be administered to the patient on a regimen of one to four doses per day.
  • compositions as described herein, the active substances, in the amounts described above, are compounded as described herein (according to accepted pharmaceutical practice) with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in the particular type of unit dosage form.
  • excipients which may be incorporated in tablets are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate or cellulose; a disintegrating agent such as corn starch, potato starch, alginic acid, sodium starch glycolate or the like; a lubricant such as stearic acid, zinc stearate or magnesium stearate; a sweetening agent such as sucrose, aspartame, lactose or saccharin; a flavoring agent such as orange, peppermint, oil of wintergreen or cherry.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • an excipient such as dicalcium phosphate or cellulose
  • a disintegrating agent such as corn starch, potato starch, alginic acid, sodium starch glycolate or the like
  • a lubricant such as stearic acid, zinc stearate or magnesium
  • the dosage unit form When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. As indicated, various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets or capsules may be coated with shellac, sugar or both.
  • a syrup of elixir may contain the active compounds, water, alcohol or the like as the carrier, glycerol as solubilizer, sucrose as sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange.
  • formulations as described above will be administered for a prolonged period, that is, for as long as the potential for cardiovascular events and disease including coronary artery disease and/or cerebrovascular disease remains or the symptoms continue.
  • Sustained release forms of such formulations which may provide such amounts daily, biweekly, weekly, monthly and the like may also be employed.
  • a dosing period of at least 10 days are required to achieve minimal benefit.
  • Formulations suitable for oral administration are prepared as described below.
  • a bilayered tablet containing aspirin in a first layer and pravastatin in a second layer as described below may be prepared as follows.
  • the aspirin granulation in the first layer is blended with sufficient quantity of the lactose/microcrystalline cellulose granulation as necessary to bulk up in order to have sufficient granulation to compress a satisfactory layer.
  • the aspirin granules along with the bulking granules are blended with zinc stearate as a lubricant.
  • Zinc stearate can be replaced with other non-alkaline lubricants, i.e., Lubritab® or other high melting point hydrogenated powdered waxes.
  • Ingredients in the second layer are wet granulated using starch paste or other wet granulating materials, for example, PVP or HPMC, or can be dry granulated by compaction.
  • the granules can be sized and lubricated.
  • the two tablet layers are compressed using appropriate conventional tools and a suitable bilayer tabletting press, to form the bilayered tablet of the invention.
  • the quantity of the buffering agents used in the second layer can be adjusted as necessary to minimize gastrointestinal side effects. It should be understood that these buffering agents can be replaced with other suitable buffering agents, if desired.
  • the so-formed bilayered tablets may be coated with HPMC (hydroxypropylmethylcellulose) or commercially available Opadry® clear or Dri Klear® (HPMC) or any of these with any desired color.
  • HPMC hydroxypropylmethylcellulose
  • HPMC commercially available Opadry® clear or Dri Klear®
  • This coat is not limited to HPMC based coats only.
  • Polymers, i.e., Eudragit E30D (acrylic acid copolymer) and others can also be used to give the tablets a finishing coat.
  • Opadry® is dispersed in water to prepare a dispersion of 10%-30% solids*. This dispersion is used for coating the above tablets using conventional coating equipment. The coating of 0.2%-2% or any desired level (based on the weight of the finished coated bilayered tablet) can be applied to the bilayered tablet employing conventional techniques.
  • the so-formed tablets provide maximum benefits while minimizing drug interaction and other undesirable side effects.
  • pravastatin contained in the buffered layer of the bilayered tablet of the invention may be replaced with equivalent cholesterol lowering amounts of simvastatin, lovastatin, atorvastatin, cerivastatin or fluvastatin.
  • Tablets or capsules containing enteric coated aspirin and a statin, which preferably is simvastatin, lovastatin or cerivastatin, having the following composition are prepared as described below.
  • Aspirin particles are coated with enteric polymers in aqueous or non-aqueous systems.
  • Eudragit L-30D-55 containing 10%-15% of diethyl phthalate (w/w) is used in an aqueous system.
  • the coating suspension is prepared having solid contents of 10%-30%.
  • the coating suspension diethyl phthalate is added to the Eudragit L-30D-55 and the contents stirred till diethyl phthalate is completely dissolved. This is diluted with water to obtain the suspension with desired solid contents.
  • the enteric coating suspension the aspirin particles are coated in a fluid bed coating system using a Wurster insert or with top spray coating, so that aspirin particles of enteric quality can be produced.
  • the enteric coated particles are mixed with statin powders or granules and the mixtures are encapsulated or tableted using appropriate excipients (fillers, binder, disintegrants, and lubricants). Any of the listed statin can be selected at its desired dose level along with the desired aspirin dose.
  • statins can also be granulated, and the statin granules and the enteric coated aspirin granules can be filled separately into the same capsule shell.
  • Statin granules can be prepared by dry or wet granulation processes, using suitable conventional excipients as is well known in the pharmaceutical field.
  • a cored tablet containing an aspirin core and a buffered coating thereon containing a statin having the following composition is prepared as described below.
  • the aspirin granulation for the core is blended with sufficient quantity of the lactose/microcrystalline cellulose granulation as necessary to bulk up in order to have sufficient granulation to compress a satisfactory core.
  • the aspirin granules along with the bulking granules are blended with zinc stearate as a lubricant.
  • Zinc stearate can be replaced with other non-alkaline lubricants, i.e., Lubritab® or other high melting point hydrogenated powdered waxes.
  • Ingredients for the outer layer are wet granulated using starch paste or other wet granulating materials, for example, PVP or HPMC, or can be dry granulated by compaction.
  • the granules can be sized and lubricated.
  • the dry coated tablets can be compressed using appropriate tools and a suitable dry coating tabletting press.
  • the quantity of the buffering agents used in the outer layer can be adjusted as in Example 1. Other known buffering agents may be used as well.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition is provided which is useful for cholesterol lowering and reducing the risk of a myocardial infarction, which includes a statin, such as pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin or fluvastatin, in combination with aspirin, in a manner to minimize interaction of aspirin with the statin and minimize side effects of aspirin. A method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition is also provided.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a pharmaceutical composition which includes a statin cholesterol lowering agent and aspirin in a manner to minimize interaction of aspirin with the statin, for use in lowering cholesterol and reducing risk of a myocardial infarction, and to a method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition. [0001]
    • BACKGROUND OF THE INVENTION
  • The use of aspirin for reducing the risk of a myocardial infarction and the use of statins for lowering cholesterol and preventing or treating atherosclerosis and cardiovascular disease and cerebrovascular disease are well documented. In fact, it is not uncommon that patients having elevated cholesterol levels who are at high risk for a myocardial infarction take both a statin and aspirin. However, use of both a statin and aspirin may require special care to insure that drug interaction, including physical and chemical incompatibility, and side effects, are kept to a minimum while achieving maximum benefit from these drugs. [0002]
  • With regard to possible drug interaction, aspirin is an acid, while some of the statins, such as pravastatin, atorvastatin and cerivastatin, are alkali salts. Thus, mixing of such statins (alkali salts) with aspirin could result in aspirin hydrolysis as well as statin degradation. Pravastatin, on the other hand, is also a very acid labile compound. When pravastatin and aspirin are combined, the aspirin could cause pravastatin degradation which could result in lower bioavailability of pravastatin. [0003]
  • Aspirin is known for causing gastrointestinal bleeding when used for long-term therapy. It is therefore desirable in long-term aspirin therapy that the aspirin be provided in a form which minimizes side effects. [0004]
  • In view of the above, it is seen that there is a long-felt want in patients required to take both a statin and aspirin for a statin-aspirin formulation which provides for maximum cholesterol lowering and reduction of risk of a myocardial infarction without the undesirable side effects and drug interaction normally associated with use of such combination. [0005]
    • DESCRIPTION OF THE INVENTION
  • In accordance with the present invention, a pharmaceutical composition is provided which includes a statin cholesterol lowering agent and aspirin, which provides for maximum patient benefits including maximum cholesterol lowering and reduced risk of a myocardial infarction with minimal physical and chemical incompatibility (including minimal statin:aspirin interaction), and reduced side effects normally associated with use of such drugs. [0006]
  • In addition, in accordance with the present invention, a method is provided for lowering serum cholesterol, preventing or inhibiting or treating atherosclerosis, and/or reducing risk of or treating a cardiovascular event or disease including coronary artery disease and cerebrovascular disease, wherein a pharmaceutical composition containing a combination of a statin cholesterol lowering agent and aspirin in a single dosage form, in a manner so as to minimize interaction of the statin and aspirin, is administered to a patient in need of treatment. [0007]
  • Preferred pharmaceutical compositions of the present invention may take the form of several different embodiments. Thus, in one embodiment of the present invention, a pharmaceutical composition is provided wherein the statin (including any statin cholesterol lowering agent) and aspirin are formulated together in a single tablet. The tablet of the invention is preferably in the form of a bilayered tablet which includes a first layer and a second layer. Aspirin, in the form of granules of preselected size will be present in the first layer together with optional excipients as described hereinafter, while the statin will be present in the second layer which optionally may include one or more buffering agents (as necessary to prevent undesirable statin/aspirin interaction) and optionally one or more excipients as described hereinafter. [0008]
  • In addition, the bilayered tablet of the invention may include an outer protective coating or finishing layer as described hereinafter. [0009]
  • Another embodiment of the present invention comprises a cored tablet which includes a core and a buffering layer or outer coat which can be compressed onto the core as a dry coat. The core will preferably include compressed aspirin granules while the buffering layer or outer coat will include a statin (including any statin cholesterol lowering agent) together with one or more buffering agents and optional excipients. [0010]
  • Provision of aspirin in the core and statin in the buffering layer will effectively reduce the aspirin side effects and also minimize drug incompatibilities while providing maximum efficacy. [0011]
  • The so-described cored tablet may also optionally include an outer protective coating or finishing layer as described hereinafter. [0012]
  • In addition, in accordance with the present invention, a pharmaceutical composition is provided which is in the form of a tablet or capsule which includes a mixture of aspirin granules having an enteric coating and particles or granules of a statin. Such a combination will provide maximum efficacy while minimizing side effects resulting from prolonged aspirin therapy. [0013]
  • In the above embodiment containing enteric coated aspirin, the statin may include any statin cholesterol lowering agent, but preferably is simvastatin, lovastatin or cerivastatin. [0014]
  • In yet another embodiment of the pharmaceutical composition of the present invention, enteric coated aspirin granules as described above may be further coated with a protective coating or finishing layer. The double coated particles of aspirin can be mixed with any statins such as pravastatin, atorvastatin, simvastatin, lovastatin, and cerivastatin powders or granules, and the mixture can be encapsulated or tableted as described herein. In such case, further coating of the enteric coated aspirin particles is desired to minimize interaction of alkaline pravastatin, atorvastatin or cerivastatin with enteric coated aspirin. This combination will protect the integrity of the enteric coat and minimize the side effects normally resulting from prolonged aspirin therapy. The aspirin and the statin granules do not need to be mixed together; these can even be encapsulated separately into the same capsule shells in two shots. [0015]
  • Another embodiment of the pharmaceutical composition of the invention includes granules of enteric coated aspirin and enteric coated statin (including any statin cholesterol lowering agent), in the same dosage form such as compressed tablets or capsules. [0016]
  • The tablets containing the enteric coated granules of aspirin and statin may also include an outer protective coating or finishing layer. [0017]
  • In a further embodiment of the pharmaceutical composition of the invention, where aspirin side effects are not an issue, for example, where low dose aspirin is present (81 mg or less), the composition of the invention may comprise a mixture of aspirin granules and statin (including any statin cholesterol lowering agent, preferably, simvastatin, lovastatin or enteric coated particles of pravastatin or particles of pravastatin, atorvastatin and cerivastatin containing an outer protective coating or finishing layer); the above mixture may take the form of compressed tablets or capsules (where the mixture can be encapsulated separately in two shots in the same capsule shells). [0018]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The pharmaceutical composition of the invention which includes a combination of a statin and aspirin is effective in preventing, reducing and/or treating elevated cholesterol levels (such as in hypercholesterolemia), atherosclerosis, cardiovascular events and disease including coronary events and cerebrovascular events, and coronary artery disease and/or cerebrovascular disease. [0019]
  • The terms “cardiovascular event(s)” and “cardiovascular disease” as employed herein refer to coronary and/or cerebrovascular event(s) and disease including primary myocardial infarction, secondary myocardial infarction, myocardial ischemia, angina pectoris (including unstable angina), congestive heart failure, sudden cardiac death, cerebral infarction, cerebral thrombosis, cerebral ischemia, transient ischemic attack and the like. [0020]
  • The term “coronary artery disease” (CAD) as employed herein refers to diseases including atherosclerosis of the coronary arteries, previous myocardial infarction, ischemia, angina pectoris and/or heart failure. [0021]
  • The term “cerebrovascular disease” as employed herein refers to diseases including atherosclerosis of the intracranial and/or extracranial arteries, cerebral infarction, cerebral thrombosis, cerebral ischemia, stroke, and/or transient ischemic attacks. [0022]
  • Aspirin will preferably be employed in the form of salicylic acid acetate also referred to as acetylsalicylic acid. [0023]
  • The pharmaceutical composition of the invention in the form of a tablet or capsule will include aspirin in amounts from about 10 to about 800 mg, preferably 50 to about 650 mg. [0024]
  • The aspirin for use in forming the pharmaceutical composition of the invention will preferably be in the form of granules having an average particle size within the range from about 10 μm to about 2 mm, more preferably from about 0.25 mm to about 1.0 mm. [0025]
  • Statin cholesterol lowering agents suitable for use herein will include HMG CoA reductase inhibitors such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin and other statins such as fluindostatin and preferably pravastatin, simvastatin, atorvastatin or cerivastatin. [0026]
  • The pharmaceutical composition of the invention will contain a statin such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in an amount as normally employed for such statin as exemplified in the 52nd edition of the Physician's Desk Reference (PDR) (1998). Thus, depending upon the particular statin, it may be employed in amounts within the range from about 0.1 mg to 2000 mg per day in single or divided doses, and preferably from about 0.2 to about 200 mg per day. Most preferably for pravastatin, a daily dosage of 10 to 40 mg may be employed; for lovastatin, a daily dosage of 10 to 80 mg may be employed, for simvastatin a daily dosage of 5 to 40 mg may be employed; for atorvastatin, a daily dosage of 10 to 80 mg may be employed, for fluvastatin, a daily dosage of 20 to 80 mg may be employed; and for cerivastatin, a daily dosage of 0.2-0.3 mg may be employed. [0027]
  • In forming the pharmaceutical composition of the invention in the form of a bilayered tablet, the first layer containing aspirin will also preferably include bulking agents such as lactose, microcrystalline cellulose, wood cellulose, corn starch, modified corn starch, calcium phosphate, sugar, dextrose, mannitol or sorbitol. The bulking agent will be present in an amount from about 1 to about 90%, preferably from about 5 to about 85% by weight of the first layer containing aspirin. [0028]
  • The first layer may also include a tabletting lubricant, such as zinc stearate, magnesium stearate, calcium stearate, talc, carnauba wax, stearic acid, palmitic acid or hydrogenated vegetable oils and fats, in an amount within the range from about 0.01 to about 4%, and preferably 0.02 to about 2% by weight of the first layer. [0029]
  • The second layer of the bilayered tablet containing statin cholesterol lowering agent will usually include a bulking agent such as lactose, microcrystalline cellulose, modified corn starch, calcium phosphate or other bulking agent as set out above for the first layer, in an amount within the range from about 1 to about 90%, preferably from about 5 to about 85% by weight of the second layer. In addition, the second layer may include a binder such as corn starch, pregelatinized starch, polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, cellulsoe acetate and the like, in an amount within the range from about 0.5 to about 20%, preferably from about 1 to about 10% by weight of the second layer, and a tabletting lubricant such as magnesium stearate, zinc stearate, or other lubricant as set out above with respect to the first layer in an amount from about 0.01 to about 4%, preferably from about 0.02 to about 2% by weight of the second layer. [0030]
  • The buffering agents present in the second layer may include conventional acid buffers such as calcium carbonate, magnesium oxide, magnesium carbonate, magnesium hydroxide, aluminum hydroxide, dihydroxyaluminum sodium carbonate, aluminum magnesium hydroxide sulfate or aluminum hydroxide magnesium carbonate co-dried gel, or mixtures of one or more thereof, in amounts as needed to insure that the aspirin will be sufficiently buffered to inhibit GI side effects. Thus, amounts of buffering agent within the range from about 10 to about 1000 mg, preferably from about 50 to about 500 mg will be employed depending upon the amount of aspirin present in the first layer. [0031]
  • In forming the bilayered tablet of the invention, the first layer containing aspirin may be prepared by conventional wet granulation or dry granulation (compaction) techniques. [0032]
  • The second layer containing statin and buffers may be prepared by conventional wet granulation or dry granulation (compaction) techniques. [0033]
  • The first and second layers may then be compressed and combined to form a bilayered tablet employing conventional bilayer tabletting equipment. [0034]
  • Other conventional ingredients which may optionally be present in either of the two layers include preservatives, stabilizers, anti-adherents or silica flow conditioners or glidants, such as Syloid brand silicon dioxide as well as antioxidants such as Vitamin E, Vitamin C, and folic acid, Vitamin B[0035] 6 and Vitamin B12.
  • The bilayer tablet of the invention may also include an outer protective coating layer which may comprise from 0 to about 15% by weight of the bilayer tablet. The outer protective coating layer which is applied over the bilayered tablet may comprise any conventional coating formulations and will include one or more film-formers or binders, such as a hydrophilic polymer like hydroxypropylmethyl cellulose (HPMC) and a hydrophobic polymer like ethyl cellulose, cellulose acetate, polyvinyl alcohol-maleic anhydride copolymers, acrylic copolymers, β-pinene polymers, glyceryl esters of wood resins and the like, and one or more plasticizers, such as polyethylene glycol, triethyl citrate, diethyl phthalate, propylene glycol, glycerin, butyl phthalate, castor oil and the like. [0036]
  • The film formers are applied from a solvent system containing one or more solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and 1,1,1-trichloroethane. [0037]
  • The pharmaceutical composition of the invention in the form of a cored tablet wherein the aspirin forms the core, and statin plus buffering agent are present in a surrounding coat layer, may be prepared employing conventional cored tablet technology. Thus, the aspirin containing core (including excipients and other ingredients as described for the first layer in the bilayered tablet of the invention) may be formed in a manner similar to the first layer of the bilayered tablet as described hereinbefore. The buffering layer containing statin as well as excipients and other ingredients (as described hereinbefore for the second layer of the bilayered tablet of the invention) may be compressed onto the core as a dry coat. [0038]
  • The so-formed cored tablet may be coated with an outer protective coating layer as described above for the bilayered tablet. [0039]
  • Another embodiment of the pharmaceutical composition of the invention is formed of tablets or capsules containing a mixture of enteric coated aspirin granules, and a statin such as lovastatin, simvastatin or cerivastatin, which may be in the form of a tablet or capsule. [0040]
  • The aspirin granules can be coated with conventional enteric polymers coatings in aqueous or non-aqueous systems. For example, Eudragit L-30D-55 (acrylic acid copolymers-Rohm Pharma) (5 to 25% solids) containing 10 to 15% of diethylphthlate (w/w) as plasticizer can be used in an aqueous system. [0041]
  • Other conventional enteric polymer coating systems may be employed such as Eudragit R and S series resins, (acrylic acid copolymers-Rohm Pharma), cellulose acetate phthalate, cellulose acetate maleate, cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethylcellulose acetate succinate, and the like, and a suitable plasticizer such as triethyl citrate, diethyl phthalate, tributyl citrate, triacetin, dibutyl phthalate dibutyl sebicate, Myvacet 940, and other commonly used plasticizers as may be suitable for particular enteric polymers can be used. It will be appreciated that any polymer with suitable plasticizer can be used in aqueous or non-aqueous system to form an enteric coating on the aspirin granule or particle. [0042]
  • In another embodiment of the pharmaceutical composition of the invention, the enteric coated aspirin granules described above may be further coated with an outer protective finishing coat or layer as described hereinbefore. [0043]
  • The double coated aspirin granules can be mixed with a statin such as pravastatin, atorvastatin, simvastatin, lovastatin, fluvastatin or cerivastatin powders or granules and the mixture can be encapsulated or tableted as described above. [0044]
  • In yet another embodiment of the pharmaceutical composition of the invention, aspirin is enteric coated as described above and the statin (pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin and cerivastatin) can optionally be enteric coated. The statins can be coated in the form of pure drugs or after spheronization or agglomeration. The particles for coating do not need to be perfectly spherical. These could be rods or irregular particles. The enteric coated particles of the two drugs (aspirin and statin) can be tableted or encapsulated together. As described above, appropriate excipients (fillers, binders, disintegrants, and lubricant, etc.) can be used to facilitate tabletting. This statin:aspirin combination will minimize side effects of aspirin, and eliminate chemical incompatibility. [0045]
  • If, aspirin side effects are not an issue, especially at lower (e.g., 80 mg) aspirin dosages, then aspirin granules (including uncoated aspirin) can be mixed with simvastatin, lovastatin and fluvastatin powder or granules for tabletting or for encapsulating. [0046]
  • In yet another embodiment, aspirin granules can be mixed with enteric coated particles of pravastatin, cerivastatin and atorvastatin and the mixture can be tableted or encapsulated or the two granules can be encapsulated in two shots in the same capsule shells. [0047]
  • In carrying out the method of the present invention, the pharmaceutical composition of the invention containing the combination of the statin cholesterol lowering drug and aspirin may be administered to mammalian species, such as monkeys, dogs, cats, rats, humans, etc., and, as described hereinbefore, may be incorporated in a tablet or capsule. The above dosage forms will also include the necessary carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), antioxidants such as Vitamin C and Vitamin E, as well as Vitamin B[0048] 6, Vitamin B12, folic acid, sodium bisulfite, and the like.
  • The dose administered must be adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result. [0049]
  • The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination. [0050]
  • Tablets of various sizes can be prepared, e.g., of about 2 to 2000 mg in total weight, containing the active substances in the ranges described above, with the remainder being a physiologically acceptable carrier of other materials according to accepted pharmaceutical practice. These tablets can, of course, be scored to provide for fractional doses in some cases. Gelatin capsules can be similarly formulated. [0051]
  • Liquid formulations can also be prepared by dissolving or suspending one or the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsful. [0052]
  • Such dosage forms can be administered to the patient on a regimen of one to four doses per day. [0053]
  • In general, formulating the compositions, as described herein, the active substances, in the amounts described above, are compounded as described herein (according to accepted pharmaceutical practice) with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in the particular type of unit dosage form. [0054]
  • Illustrative of the excipients which may be incorporated in tablets are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate or cellulose; a disintegrating agent such as corn starch, potato starch, alginic acid, sodium starch glycolate or the like; a lubricant such as stearic acid, zinc stearate or magnesium stearate; a sweetening agent such as sucrose, aspartame, lactose or saccharin; a flavoring agent such as orange, peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. As indicated, various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets or capsules may be coated with shellac, sugar or both. A syrup of elixir may contain the active compounds, water, alcohol or the like as the carrier, glycerol as solubilizer, sucrose as sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange. [0055]
  • Some of the active substances described above form commonly known, pharmaceutically acceptable salts such as alkali metal and other common basic salts or acid addition salts, etc. References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent compound. [0056]
  • The formulations as described above will be administered for a prolonged period, that is, for as long as the potential for cardiovascular events and disease including coronary artery disease and/or cerebrovascular disease remains or the symptoms continue. Sustained release forms of such formulations which may provide such amounts daily, biweekly, weekly, monthly and the like may also be employed. A dosing period of at least 10 days are required to achieve minimal benefit.[0057]
  • The following Examples represent preferred embodiments of the present invention. [0058]
  • Formulations suitable for oral administration are prepared as described below. [0059]
    • EXAMPLE 1
  • A bilayered tablet containing aspirin in a first layer and pravastatin in a second layer as described below may be prepared as follows. [0060]
    General Formula:
    Amount or %
    First Layer: in First Layer
    Aspirin granulation 80 mg-325 mg
    Lactose/microcrystalline qs
    Cellulose granulation*
    Zinc Stearate 0.1%-0.5   
    Amount in Second
    Second Layer: Layer
    Calcium Carbonate 50 mg-250 mg
    Magnesium Oxide 50 mg-100 mg
    Magnesium Carbonate 25 mg-50 mg 
    Corn Starch 25 mg-50 mg 
    Pravastatin 20 mg-40 mg 
    Magnesium stearate 0.2%-0.5%
  • Procedure: [0061]
  • The aspirin granulation in the first layer is blended with sufficient quantity of the lactose/microcrystalline cellulose granulation as necessary to bulk up in order to have sufficient granulation to compress a satisfactory layer. The aspirin granules along with the bulking granules are blended with zinc stearate as a lubricant. Zinc stearate can be replaced with other non-alkaline lubricants, i.e., Lubritab® or other high melting point hydrogenated powdered waxes. [0062]
  • Ingredients in the second layer are wet granulated using starch paste or other wet granulating materials, for example, PVP or HPMC, or can be dry granulated by compaction. The granules can be sized and lubricated. The two tablet layers are compressed using appropriate conventional tools and a suitable bilayer tabletting press, to form the bilayered tablet of the invention. [0063]
  • The quantity of the buffering agents used in the second layer can be adjusted as necessary to minimize gastrointestinal side effects. It should be understood that these buffering agents can be replaced with other suitable buffering agents, if desired. [0064]
  • The so-formed bilayered tablets may be coated with HPMC (hydroxypropylmethylcellulose) or commercially available Opadry® clear or Dri Klear® (HPMC) or any of these with any desired color. This coat is not limited to HPMC based coats only. Polymers, i.e., Eudragit E30D (acrylic acid copolymer) and others can also be used to give the tablets a finishing coat. [0065]
    Coating Formula (example):
    Opadry ® clear 10%-30%
    Purified water qs
  • Procedure: [0066]
  • Opadry® is dispersed in water to prepare a dispersion of 10%-30% solids*. This dispersion is used for coating the above tablets using conventional coating equipment. The coating of 0.2%-2% or any desired level (based on the weight of the finished coated bilayered tablet) can be applied to the bilayered tablet employing conventional techniques. [0067]
  • The so-formed tablets provide maximum benefits while minimizing drug interaction and other undesirable side effects. [0068]
  • It will be understood that pravastatin contained in the buffered layer of the bilayered tablet of the invention may be replaced with equivalent cholesterol lowering amounts of simvastatin, lovastatin, atorvastatin, cerivastatin or fluvastatin. [0069]
    • EXAMPLE 2
  • Tablets or capsules containing enteric coated aspirin and a statin, which preferably is simvastatin, lovastatin or cerivastatin, having the following composition are prepared as described below. [0070]
    General Formula:
    Aspirin particles 80 mg-325 mg
    Eudragit L-30D-55 qs
    Diethyl Phthalate qs
    Statins (simvastatin, lovastatin, Desired Dose (as
    or cerivastatin) per PDR)
  • Procedure: [0071]
  • Aspirin particles are coated with enteric polymers in aqueous or non-aqueous systems. Eudragit L-30D-55 containing 10%-15% of diethyl phthalate (w/w) is used in an aqueous system. The coating suspension is prepared having solid contents of 10%-30%. [0072]
  • To prepare the coating suspension, diethyl phthalate is added to the Eudragit L-30D-55 and the contents stirred till diethyl phthalate is completely dissolved. This is diluted with water to obtain the suspension with desired solid contents. Using this enteric coating suspension, the aspirin particles are coated in a fluid bed coating system using a Wurster insert or with top spray coating, so that aspirin particles of enteric quality can be produced. The enteric coated particles are mixed with statin powders or granules and the mixtures are encapsulated or tableted using appropriate excipients (fillers, binder, disintegrants, and lubricants). Any of the listed statin can be selected at its desired dose level along with the desired aspirin dose. [0073]
  • The statins can also be granulated, and the statin granules and the enteric coated aspirin granules can be filled separately into the same capsule shell. Statin granules can be prepared by dry or wet granulation processes, using suitable conventional excipients as is well known in the pharmaceutical field. [0074]
  • The above formulations provide maximum benefit while minimizing undesirable side effects and incompatibilities. [0075]
    • EXAMPLE 3
  • A cored tablet containing an aspirin core and a buffered coating thereon containing a statin having the following composition is prepared as described below. [0076]
    General Formula:
    Amount or %
    Core Layer: in Core Layer
    Aspirin granulation 80 mg-325 mg
    Lactose/microcrystalline qs
    Cellulose granulation*
    Zinc Stearate 0.1%-0.5   
    Amount in Second
    Outer Layer: Layer
    Calcium Carbonate 50 mg-250 mg
    Magnesium Oxide 50 mg-100 mg
    Magnesium Carbonate 25 mg-50 mg 
    Corn Starch 25 mg-50 mg 
    Pravastatin 20 mg-30 mg 
    Magnesium stearate 0.2%-0.5%
    Filler/Binder** qs
    # also do not contain excessive moisture and are compatible with aspirin granules. These bulking granules must have enough compatibility to allow compression of two layer tablets).
  • Procedure: [0077]
  • The aspirin granulation for the core is blended with sufficient quantity of the lactose/microcrystalline cellulose granulation as necessary to bulk up in order to have sufficient granulation to compress a satisfactory core. The aspirin granules along with the bulking granules are blended with zinc stearate as a lubricant. Zinc stearate can be replaced with other non-alkaline lubricants, i.e., Lubritab® or other high melting point hydrogenated powdered waxes. [0078]
  • Ingredients for the outer layer are wet granulated using starch paste or other wet granulating materials, for example, PVP or HPMC, or can be dry granulated by compaction. The granules can be sized and lubricated. The dry coated tablets can be compressed using appropriate tools and a suitable dry coating tabletting press. [0079]
  • The quantity of the buffering agents used in the outer layer can be adjusted as in Example 1. Other known buffering agents may be used as well. [0080]

Claims (26)

What is claimed is:
1. A pharmaceutical composition comprising a statin cholesterol lowering agent and aspirin in a formulation designed to minimize statin:aspirin interaction.
2. The pharmaceutical composition as defined in claim 1 wherein the statin and aspirin are formulated together in the same dosage formulation.
3. The pharmaceutical composition as defined in claim 2 wherein the statin and aspirin are formulated together in a single tablet.
4. The pharmaceutical composition as defined in claim 3 wherein the tablet is a bilayered tablet wherein the aspirin is present in a first layer, and the statin is present in a second layer.
5. The pharmaceutical composition as defined in claim 4 wherein the layer containing the statin also includes one or more buffering agents.
6. The pharmaceutical composition as defined in claim 3 wherein the tablet includes a core and a coating layer surrounding said core and wherein one of the statin and aspirin is present in the core and the other is present in the coating layer surrounding the core.
7. The pharmaceutical composition as defined in claim 6 wherein the aspirin is present in the core and the statin is present in the coating layer.
8. The pharmaceutical composition as defined in claim 7 wherein the coating layer also includes one or more buffering agents.
9. The pharmaceutical composition as defined in claim 1 wherein the statin is pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin or cerivastatin.
10. The pharmaceutical composition as defined in claim 1 further including one or more buffering agents in combination with the statin.
11. The pharmaceutical composition as defined in claim 3 further including an outer protective coating or finishing layer surrounding said tablet.
12. The pharmaceutical composition as defined in claim 1 wherein the aspirin is in the form of enteric coated aspirin granules.
13. The pharmaceutical composition as defined in claim 12 in the form of tablets or granules contained in a capsule.
14. The pharmaceutical composition as defined in claim 12 wherein the enteric coated aspirin granules include a finishing overcoat, and the coated aspirin and statin are in the form of a tablet or capsule.
15. The pharmaceutical composition as defined in claim 14 wherein the coated aspirin granules and statin granules are encapsulated separately into the same capsule shells.
16. The pharmaceutical composition as defined in claim 2 wherein the aspirin is in the form of enteric coated granules of aspirin and the statin is in the form of enteric coated granules of statin, in the form of compressed tablets or capsules.
17. The pharmaceutical composition as defined in claim 1 in the form of a tablet or capsule containing both aspirin granules and statin granules.
18. The pharmaceutical composition as defined in claim 17 wherein the statin is in the form of enteric coated statin granules.
19. The pharmaceutical composition as defined in claim 17 wherein the statin granules include an outer protective coating to minimize interaction with aspirin.
20. The pharmaceutical composition as defined in claim 1 in the form of a bilayered tablet which comprises a first layer comprising aspirin granules and one or more excipients, and a second layer comprising a statin and one or more buffering compounds and one or more excipients.
21. The pharmaceutical composition as defined in claim 20 wherein the first layer comprises aspirin granules, one or more bulking agents and optionally a lubricant, and the second layer comprises a statin, optionally a wet granulating agent, one or more buffering compounds selected from the group consisting of calcium carbonate, magnesium oxide, magnesium carbonate and mixtures thereof, and optionally magnesium stearate.
22. The pharmaceutical composition as defined in claim 20 further including an outer protective coating surrounding said bilayered tablet.
23. The pharmaceutical composition as defined in claim 1 further including an antioxidant.
24. The pharmaceutical composition as defined in claim 23 wherein the antioxidant is vitamin C and/or vitamin E.
25. A method for lowering serum cholesterol or preventing or inhibiting or treating atherosclerosis or reducing risk of or treating a cardiovascular event or desease, coronary artery disease or cerebrovascular disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a pharmaceutical composition comprising a combination of a statin cholesterol lowering agent and aspirin in a single dosage form, which dosage form minimizes interaction between the statin and aspirin, and reduces the side effects of aspirin.
26. The method as defined in claim 25 wherein the statin employed is pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin.
US09/824,364 1998-03-18 2001-04-02 Pharmaceutical composition containing a combination of a statin and aspirin and method Abandoned US20020034546A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/824,364 US20020034546A1 (en) 1998-03-18 2001-04-02 Pharmaceutical composition containing a combination of a statin and aspirin and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,794 US6235311B1 (en) 1998-03-18 1998-03-18 Pharmaceutical composition containing a combination of a statin and aspirin and method
US09/824,364 US20020034546A1 (en) 1998-03-18 2001-04-02 Pharmaceutical composition containing a combination of a statin and aspirin and method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/040,794 Division US6235311B1 (en) 1998-03-18 1998-03-18 Pharmaceutical composition containing a combination of a statin and aspirin and method

Publications (1)

Publication Number Publication Date
US20020034546A1 true US20020034546A1 (en) 2002-03-21

Family

ID=21912994

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/040,794 Expired - Lifetime US6235311B1 (en) 1998-03-18 1998-03-18 Pharmaceutical composition containing a combination of a statin and aspirin and method
US09/824,364 Abandoned US20020034546A1 (en) 1998-03-18 2001-04-02 Pharmaceutical composition containing a combination of a statin and aspirin and method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/040,794 Expired - Lifetime US6235311B1 (en) 1998-03-18 1998-03-18 Pharmaceutical composition containing a combination of a statin and aspirin and method

Country Status (12)

Country Link
US (2) US6235311B1 (en)
EP (1) EP1071403B1 (en)
JP (1) JP4541543B2 (en)
AR (1) AR018777A1 (en)
AT (1) ATE300284T1 (en)
AU (1) AU760520B2 (en)
BR (1) BR9908690A (en)
CA (1) CA2324283C (en)
DE (1) DE69926351T2 (en)
ES (1) ES2245092T3 (en)
PE (1) PE20000349A1 (en)
WO (1) WO1999047123A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019319A1 (en) * 2003-07-23 2005-01-27 Nerenberg Arnold P. Composition for mitigating a pernicious thrombotic event
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US20060025486A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and B vitamins and their pharmaceutical uses
KR100646576B1 (en) 2005-02-15 2006-11-23 한국유나이티드제약 주식회사 Combined Pellets Containing HMG-CO Reductase Inhibitor and Enteric-Coated Aspirin for Prevention of Atherosclerosis in Patients with Hyperlipidemia
KR100648825B1 (en) 2005-02-22 2006-11-24 한국유나이티드제약 주식회사 Complex pellets containing hypoglycemic agents, HM-CO reductase inhibitors and enteric-coated aspirin to prevent atherosclerosis in diabetic patients
WO2004108056A3 (en) * 2003-06-10 2008-01-10 Medley S A Ind Farmaceutica Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease
WO2008069546A1 (en) * 2006-12-07 2008-06-12 Boryung Pharmaceutical Co., Ltd Oral administrative preparation for treating cardiovascular system disease
US20090098200A1 (en) * 2007-09-25 2009-04-16 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090131376A1 (en) * 2007-10-17 2009-05-21 Ovokaitys Todd F Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
CN101491508B (en) * 2009-01-23 2011-04-20 上海微丸医药开发有限公司 Preparation method of aspirin Intestine-soluble micro-pill capsules
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
WO2012081905A3 (en) * 2010-12-17 2012-08-23 Hanmi Science Co., Ltd. Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
WO2012124973A3 (en) * 2011-03-15 2012-11-08 Boryung Pharmaceutical Co., Ltd Combined formulation with improved stability
WO2013133620A1 (en) * 2012-03-09 2013-09-12 Yuhan Corporation Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same
US20130296237A1 (en) * 2005-11-09 2013-11-07 The Washington University Use Of Chloroquine To Treat Metabolic Syndrome
TWI481407B (en) * 2007-10-17 2015-04-21 Todd F Ovokaitys Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
US9095519B2 (en) * 2007-02-09 2015-08-04 Alphapharm Pty Ltd Dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2081550B1 (en) 2006-03-09 2018-04-18 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US12246037B2 (en) 2020-12-08 2025-03-11 Todd Frank Ovokaitys Methods and systems for increased production of stem cells

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
SI20109A (en) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
CN1092986C (en) * 1999-08-16 2002-10-23 上海本草生物医学工程研究所 CoA oral preparation for reducing blood fat and its preparation method
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
HUP0203451A3 (en) 2000-08-09 2004-05-28 Panacea Biotec Ltd Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156422A0 (en) 2001-01-26 2004-01-04 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2563051A1 (en) 2001-01-26 2002-08-01 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1372616A4 (en) * 2001-03-27 2004-06-23 Ranbaxy Lab Ltd A stable pharmaceutical composition of pravastatin
US20080199522A1 (en) * 2001-04-12 2008-08-21 Astellas Pharma, Inc. Timed-release compression-coated solid composition for oral administration
EP1404303A4 (en) * 2001-06-21 2006-03-15 Andrx Pharmaceuticals Inc Stable pharmaceutical compositions containing pravastatin
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
AR036354A1 (en) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd SOLID PREPARATION
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE345793T1 (en) 2001-09-21 2006-12-15 Schering Corp TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2003055467A1 (en) * 2001-12-18 2003-07-10 Synthon B.V. Simvastatin dosage forms
KR100851770B1 (en) * 2002-01-16 2008-08-13 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
BE1015608A6 (en) * 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
US20040137054A1 (en) * 2002-05-03 2004-07-15 Alexandra Hager Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
WO2004043456A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP4494712B2 (en) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 Multiple unit type sustained release formulation
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004054548A1 (en) * 2002-12-12 2004-07-01 Activbiotics,Inc. Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
EP1581210B1 (en) * 2002-12-20 2008-03-19 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2006519869A (en) 2003-03-07 2006-08-31 シェーリング　コーポレイション Substituted azetidinone compounds, processes for preparing substituted azetidinone compounds, their formulations and uses
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2318274T3 (en) 2003-03-07 2009-05-01 Schering Corporation AZETIDINONA SUBSTITUTED COMPOUNDS, FORMULATIONS AND USE OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA.
ATE406364T1 (en) 2003-03-07 2008-09-15 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
ES2278314T3 (en) * 2003-04-17 2007-08-01 Jallal Messadek ORAL FORMULATIONS FOR THE CONTROLLED RELEASE OF THE BETA.
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
WO2004110427A1 (en) * 2003-06-18 2004-12-23 Institut De Cardiologie De Montréal /Montréal Heart Institute Preventing atrial fibrillation (af) with the use of statin drugs
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2005011586A2 (en) 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
ZA200601804B (en) * 2003-10-10 2007-05-30 Solvay Pharm Gmbh Pharmaceutcal composition comprising a selective II imidazoline receptor agonist and an angiotensin II receptor blocker
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US8535716B2 (en) * 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20090098201A1 (en) * 2004-06-28 2009-04-16 Bio Intellectual Property Services (Bio Ips) Llc Composition and Method for Treatment and Prevention of Atherosclerosis
BE1016128A6 (en) * 2004-07-22 2006-03-07 Messadek Jallal Combination therapy
US20060034913A1 (en) * 2004-08-13 2006-02-16 James Gaede Multiplex drug delivery device
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
DE102004042139B4 (en) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Peroral dosage forms to achieve a retarding effect after drug intake with a meal
US20060069042A1 (en) * 2004-09-24 2006-03-30 Hu Oliver Y Cytochrome P450 2C9 inhibitors
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
ES2255426B1 (en) 2004-10-19 2007-08-16 Gp Pharm, S.A. PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA).
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
US8030350B2 (en) 2005-02-24 2011-10-04 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
CA2650556A1 (en) * 2005-04-27 2006-11-02 Jallal Messadek Insulins combinations
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
CA2615944A1 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
BRPI0616223A2 (en) * 2005-09-15 2011-06-14 Otsuka Pharma Co Ltd drug combination
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007127377A2 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Combinations comprising omega-3 fatty acid compounds for the treatment of cardiovascular disease
BRPI0602179A (en) * 2006-06-08 2008-01-22 Biolab Sanus Farmaceutica Ltda pharmaceutical composition comprising cyclobenzaprine and aceclofenac in combination
US20070287727A1 (en) * 2006-06-08 2007-12-13 Jacob Hiller Anti-Nicotine Treatment
EP2051583A4 (en) * 2006-08-16 2011-09-14 Aspreva Pharmaceuticals Ltd Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
ES2312308T3 (en) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Topiramate sustained release formulations
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
WO2009022821A2 (en) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
CN101980701A (en) * 2008-03-28 2011-02-23 菲尔若国际公司 Capsules for the prevention of cardiovascular disease
TWI445716B (en) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9 antagonists
BRPI0924198A2 (en) * 2009-01-22 2016-02-16 Sanofi Sa combination of active ingredients containing a non-steroidal anti-inflammatory drug and a colchicide derivative
CN101897710A (en) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 Medicament composition containing HMG-CoA reductase inhibitor, aspirin and folic acid and application thereof
CA2765697C (en) 2009-06-22 2019-11-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
GEP20146015B (en) 2009-06-25 2014-01-27 Tetra Sia Novel acetylsalicylic acid salts
KR101193493B1 (en) * 2010-02-02 2012-10-22 한미사이언스 주식회사 Composite formulation comprising aspirin coated with barrier containing water-insoluble additive and HMG-CoA reductase inhibitor
US9535075B2 (en) 2010-03-25 2017-01-03 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
EP2575487B1 (en) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
TR201005325A2 (en) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Pharmaceutical formulations containing atorvastatin and aspirin
WO2012087090A1 (en) * 2010-12-21 2012-06-28 Laboratorios Silanes S.A. De C.V. Stable composition of cholesterol-reducing agents, antihypertensives and platelet-antiaggregating agents
AR086675A1 (en) * 2011-06-14 2014-01-15 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF INHIBITORS OF DIPEPTIDIL PEPTIDASA-4 WITH SIMVASTATIN
KR101952478B1 (en) 2011-11-30 2019-02-26 다케다 야쿠힌 고교 가부시키가이샤 Dry coated tablet
US20150133390A1 (en) * 2012-01-27 2015-05-14 National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Govt. Identification of New Therapeutic Uses for Known Therapeutic Agents
WO2013152230A1 (en) * 2012-04-04 2013-10-10 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
US20140274990A1 (en) * 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
LV14963B (en) 2013-06-28 2015-10-20 Tetra, Sia Corrector of endothelial dysfunction
US20150072005A1 (en) * 2013-09-10 2015-03-12 Vitalis Llc Aspirin formulation for increased efficacy
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
BE1023011B1 (en) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylic acid tablet with immediate release
FR3040303B1 (en) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITOR AND ECA INHIBITOR
EP3432929A4 (en) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
FR3060390B1 (en) * 2016-12-19 2020-09-25 Bh Pharma FORMULATION CONSISTING OF PRAVASTATIN AND ACETYLSALYCILIC ACID
BR112019015107A2 (en) * 2017-01-23 2020-03-10 Dong Wha Pharm. Co., Ltd. COMPLEX FORMULATION UNDERSTANDING HMG-COA REDUCTASE AND CLOPIDOGREL INHIBITOR
US11185530B2 (en) * 2017-03-09 2021-11-30 Ajou University Industry-Academic Cooperation Foundation Composition for preventing or treating hearing loss, containing atorvastatin as active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
USH1286H (en) * 1989-06-05 1994-02-01 E. R. Squibb & Sons, Inc. Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ace inhibitor, or a combination thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642233A (en) * 1982-03-22 1987-02-10 Alza Corporation Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills
DK8603837A (en) * 1985-08-13 1987-02-14
US5415870A (en) * 1991-07-01 1995-05-16 Gerhard Gergely Effervescent systems using reaction doping agents
HU217629B (en) * 1991-12-12 2000-03-28 Novartis Ag. A method for the preparation of stabilized pharmaceutical compositions containing fluvastatin
JP3152978B2 (en) * 1991-12-17 2001-04-03 塩野義製薬株式会社 Double-layer tablet and method for producing the same
WO1993013801A1 (en) 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
JPH08325145A (en) * 1995-05-26 1996-12-10 Sumitomo Pharmaceut Co Ltd Stable isopropyl antipyrine containing formulations
EP0904082A4 (en) * 1996-04-17 2001-09-26 Merck & Co Inc Combination therapy for reducing the risks associated with cardiovascular disease
WO1998011896A1 (en) 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
USH1286H (en) * 1989-06-05 1994-02-01 E. R. Squibb & Sons, Inc. Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ace inhibitor, or a combination thereof
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108056A3 (en) * 2003-06-10 2008-01-10 Medley S A Ind Farmaceutica Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease
US7041286B2 (en) 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
US20050019319A1 (en) * 2003-07-23 2005-01-27 Nerenberg Arnold P. Composition for mitigating a pernicious thrombotic event
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US20060025486A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and B vitamins and their pharmaceutical uses
KR100646576B1 (en) 2005-02-15 2006-11-23 한국유나이티드제약 주식회사 Combined Pellets Containing HMG-CO Reductase Inhibitor and Enteric-Coated Aspirin for Prevention of Atherosclerosis in Patients with Hyperlipidemia
KR100648825B1 (en) 2005-02-22 2006-11-24 한국유나이티드제약 주식회사 Complex pellets containing hypoglycemic agents, HM-CO reductase inhibitors and enteric-coated aspirin to prevent atherosclerosis in diabetic patients
US20130296237A1 (en) * 2005-11-09 2013-11-07 The Washington University Use Of Chloroquine To Treat Metabolic Syndrome
EP2081550B1 (en) 2006-03-09 2018-04-18 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
WO2008069546A1 (en) * 2006-12-07 2008-06-12 Boryung Pharmaceutical Co., Ltd Oral administrative preparation for treating cardiovascular system disease
KR100870396B1 (en) * 2006-12-07 2008-11-25 보령제약 주식회사 Oral administrative dosage form for treating cardiovascular system disease
US9095519B2 (en) * 2007-02-09 2015-08-04 Alphapharm Pty Ltd Dosage form containing two or more active pharmaceutical ingredients in different physical forms
US9254268B2 (en) 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090098200A1 (en) * 2007-09-25 2009-04-16 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
EP2601935A1 (en) 2007-09-25 2013-06-12 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
TWI481407B (en) * 2007-10-17 2015-04-21 Todd F Ovokaitys Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
US8173632B2 (en) * 2007-10-17 2012-05-08 Todd F. Ovokaitys Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
US20090131376A1 (en) * 2007-10-17 2009-05-21 Ovokaitys Todd F Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
CN101491508B (en) * 2009-01-23 2011-04-20 上海微丸医药开发有限公司 Preparation method of aspirin Intestine-soluble micro-pill capsules
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
CN103282027A (en) * 2010-12-17 2013-09-04 韩美科学株式会社 Pharmaceutical composite formulation comprising hmg-oa reductase inhibitor and aspirin
EP2651401A4 (en) * 2010-12-17 2016-10-05 Hanmi Science Co Ltd COMPOSITE PHARMACEUTICAL FORMULATION COMPRISING AN INHIBITOR OF HMG-COA REDUCTASE, AND ASPIRIN
WO2012081905A3 (en) * 2010-12-17 2012-08-23 Hanmi Science Co., Ltd. Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
WO2012124973A3 (en) * 2011-03-15 2012-11-08 Boryung Pharmaceutical Co., Ltd Combined formulation with improved stability
WO2013133620A1 (en) * 2012-03-09 2013-09-12 Yuhan Corporation Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10907144B2 (en) 2014-05-30 2021-02-02 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US11905510B2 (en) 2014-05-30 2024-02-20 Todd Frank Ovokaitys Methods and systems for activating cells to treat aging
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US10865157B2 (en) 2014-06-06 2020-12-15 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US12246037B2 (en) 2020-12-08 2025-03-11 Todd Frank Ovokaitys Methods and systems for increased production of stem cells

Also Published As

Publication number Publication date
US6235311B1 (en) 2001-05-22
EP1071403A1 (en) 2001-01-31
JP2002506809A (en) 2002-03-05
ATE300284T1 (en) 2005-08-15
JP4541543B2 (en) 2010-09-08
CA2324283C (en) 2009-11-03
WO1999047123A1 (en) 1999-09-23
EP1071403B1 (en) 2005-07-27
AU2901599A (en) 1999-10-11
CA2324283A1 (en) 1999-09-23
AU760520B2 (en) 2003-05-15
ES2245092T3 (en) 2005-12-16
PE20000349A1 (en) 2000-06-29
DE69926351D1 (en) 2005-09-01
AR018777A1 (en) 2001-12-12
DE69926351T2 (en) 2006-04-20
EP1071403A4 (en) 2002-09-18
BR9908690A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
US6235311B1 (en) Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1581194B1 (en) Multilayered tablet containing pravastatin and aspirin and method
US5041430A (en) Oral anticoagulant/platelet inhibitor low dose formulation
KR101298788B1 (en) A combined formulation with improved stability
US20010003588A1 (en) Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US20120045505A1 (en) Fixed dose drug combination formulations
WO2000033821A1 (en) Enteric coated pravastatin bead formulation
EP0320097B1 (en) Controlled absorption diltiazem formulations
US20050239884A1 (en) Compositions comprising hmg-coa reductase inhibitor
CA2793222C (en) Stabilized formulations of cns compounds
EP1404301A2 (en) Stable controlled release pharmaceutical compositions containing pravastatin
US20070218134A1 (en) Compositions Comprising Organic Compounds
MXPA00008429A (en) Pharmaceutical composition containing a statin and aspirin
US20090098201A1 (en) Composition and Method for Treatment and Prevention of Atherosclerosis
US20040180087A1 (en) Stable controlled release pharmaceutical compositions containing pravastatin
MX2007008440A (en) Combined pharmaceutical composition.
US20070160663A1 (en) Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
EP1377277B1 (en) Pharmaceutical compositions comprising pravastatin for reducing ldl cholesterol levels
KR101072600B1 (en) Stable pharmaceutical composition comprising fluvastatin and method for preparing the same
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride
AU2002312297A1 (en) Stable controlled release pharmaceutical compositions containing pravastatin

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载